RAPT Company Profile and Key Details

Q: Who are the executives of RAPT?

Ms. Jennifer NicholsonSenior Vice President of Regulatory Affairs & Quality AssuranceMs. Gwen R. CarscaddenChief HR OfficerDr. William HoChief Medical OfficerDr. David WustrowSenior Vice President of Drug Discovery & Preclinical Devel.Dr. Dirk G. Brockstedt Ph.D.Chief Scientific OfficerDr. Brian Russell Wong M.D., Ph.D.Chief Executive Officer, Pres & DirectorSteve Young Ph.D.Vice President of TechnologyDr. Paul KassnerSenior Vice President of Quantitative & Computational BiologyMr. Rodney K. B. YoungChief Financial Officer, Principal Accounting Officer & Sec.Mr. Michael ListgartenGen. Counsel

NASDAQ : RAPT

RAPT Therapeutics

$57.60

0.0306+0.05%

Open: 12:27 PM

56.57

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

RAPT Therapeutics, Inc. (RAPT) stock surged +0.05%, trading at $57.60 on NASDAQ, up from the previous close of $57.57. The stock opened at $57.54, fluctuating between $57.54 and $57.62 in the recent session.

Stock Snapshot

57.57

Prev. Close

952.57M

Market Cap

57.54

Day Low

-4.94

P/E Ratio

-11.66

EPS (TTM)

-2.56

Cash Flow per Share

57.54

Open

16.54M

Number of Shares

57.62

Day High

50.59%

Free Float in %

3.83

Book Value

1.04M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 20, 2026	57.47	57.61	57.46	57.57	31.75M
Jan 16, 2026	32.01	35.47	32.00	35.10	424.35K
Jan 15, 2026	34.94	34.94	32.06	32.19	212.92K
Jan 14, 2026	34.05	35.42	33.96	34.73	137.32K
Jan 13, 2026	34.27	34.86	32.99	34.06	176.11K
Jan 12, 2026	33.58	34.52	32.14	34.40	177.97K
Jan 09, 2026	32.88	33.72	32.06	33.62	338.06K
Jan 08, 2026	32.42	32.50	31.18	31.20	310.99K
Jan 07, 2026	31.08	33.24	31.08	32.42	426.93K
Jan 06, 2026	29.82	32.10	29.77	30.83	288.25K
Jan 05, 2026	31.78	32.67	29.77	29.82	465.39K
Jan 02, 2026	33.93	34.15	31.62	31.85	257.7K
Dec 31, 2025	33.15	34.22	33.15	33.87	227.55K
Dec 30, 2025	35.59	35.95	33.01	33.38	293.06K
Dec 29, 2025	35.02	36.25	34.78	35.84	413.04K
Dec 26, 2025	35.68	35.71	34.80	35.42	115.59K
Dec 24, 2025	35.58	36.92	34.38	35.84	236.37K
Dec 23, 2025	36.17	36.74	35.10	35.40	147.49K
Dec 22, 2025	34.29	37.75	33.94	36.47	553.94K
Dec 19, 2025	33.84	35.78	33.45	33.81	1.71M

Contact Details

South San Francisco, CA 94080

United States

https://www.rapt.com 650 489 9000

About Company

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Stock Peers

ARGX

9.63+1.20%

argenx SE$809.64 REGN

0.74+0.10%

Regeneron Pharmaceuticals, Inc.$733.78 MDGL

3.27+0.65%

Madrigal Pharmaceuticals, Inc.$504.95 UTHR

3.14+0.68%

United Therapeutics Corporation$468.07 VRTX

0.72+0.16%

Vertex Pharmaceuticals Incorporated$442.08 ALNY

-3.74-1.04%

Alnylam Pharmaceuticals, Inc.$355.53 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

6.83+2.15%

Praxis Precision Medicines, Inc.$324.08 KRYS

-10.23-3.59%

Krystal Biotech, Inc.$274.81 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Frequently Asked Questions

What is the current RAPT Therapeutics, Inc. (RAPT) stock price?

RAPT Therapeutics, Inc. (NASDAQ: RAPT) stock price is $57.60 in the last trading session. During the trading session, RAPT stock reached the peak price of $57.62 while $57.54 was the lowest point it dropped to. The percentage change in RAPT stock occurred in the recent session was 0.05% while the dollar amount for the price change in RAPT stock was $0.03.

RAPT's industry and sector of operation?

The NASDAQ listed RAPT is part of Biotechnology industry that operates in the broader Healthcare sector. RAPT Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RAPT?

Ms. Jennifer Nicholson
Senior Vice President of Regulatory Affairs & Quality Assurance
Ms. Gwen R. Carscadden
Chief HR Officer
Dr. William Ho
Chief Medical Officer
Dr. David Wustrow
Senior Vice President of Drug Discovery & Preclinical Devel.
Dr. Dirk G. Brockstedt Ph.D.
Chief Scientific Officer
Dr. Brian Russell Wong M.D., Ph.D.
Chief Executive Officer, Pres & Director
Steve Young Ph.D.
Vice President of Technology
Dr. Paul Kassner
Senior Vice President of Quantitative & Computational Biology
Mr. Rodney K. B. Young
Chief Financial Officer, Principal Accounting Officer & Sec.
Mr. Michael Listgarten
Gen. Counsel

How RAPT did perform over past 52-week?

RAPT's closing price is 916.42% higher than its 52-week low of $5.66 where as its distance from 52-week high of $57.62 is -0.07%.

How many employees does RAPT have?

Number of RAPT employees currently stands at 67.

Link for RAPT official website?

Official Website of RAPT is: https://www.rapt.com

How do I contact RAPT?

RAPT could be contacted at phone 650 489 9000 and can also be accessed through its website. RAPT operates from 561 Eccles Avenue, South San Francisco, CA 94080, United States.

How many shares of RAPT are traded daily?

RAPT stock volume for the day was 1.04M shares. The average number of RAPT shares traded daily for last 3 months was 970.85K.

What is the market cap of RAPT currently?

The market value of RAPT currently stands at $952.57M with its latest stock price at $57.60 and 16.54M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	67
Beta	0.46
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	67
Beta	0.46
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RAPT Company Profile and Key Details

RAPT Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways